MedTrace Logo

Retrospective Observational Safety Effectiveness With Kuvan in hpA

NCT03864029 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 26

Last updated 2019-03-07

No results posted yet for this study

Summary

A retrospective study to collect the effectiveness and safety data of the past treatment with KUVAN in Chinese patients with HPA caused by BH4 deficiency. The data was collected from relevant past medical history and past clinical and safety assessments.

Conditions

  • Tetrahydrobiopterin Deficiency

Interventions

DRUG

KUVAN

retrospective data on the effectiveness of past treatment with KUVAN®. It includes blood Phe level, physical development status, intelligence development status, etc., during treatment with KUVAN

Sponsors & Collaborators

Principal Investigators

  • Medical Director, MD · Medical Director

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-10
Primary Completion
2018-03-09
Completion
2018-07-25
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03864029 on ClinicalTrials.gov